These Algorithms Look at X-Rays—and Somehow Detect Your Race
By Tom Simonite,
Wired
| 08. 05. 2021
A study raises new concerns that AI will exacerbate disparities in health care. One issue? The study’s authors aren’t sure what cues are used by the algorithms.
Photo licensed for use by CC BY-SA 4.0 on Wikimedia Commons
Millions of dollars are being spent to develop artificial intelligence software that reads x-rays and other medical scans in hopes it can spot things doctors look for but sometimes miss, such as lung cancers. A new study reports that these algorithms can also see something doctors don’t look for on such scans: a patient’s race.
The study authors and other medical AI experts say the results make it more crucial than ever to check that health algorithms perform fairly on people with different racial identities. Complicating that task: The authors themselves aren’t sure what cues the algorithms they created use to predict a person’s race.
Evidence that algorithms can read race from a person’s medical scans emerged from tests on five types of imagery used in radiology research, including chest and hand x-rays and mammograms. The images included patients who identified as Black, white, and Asian. For each type of scan, the researchers trained algorithms using images labeled with a patient’s self-reported race. Then they challenged the algorithms to predict...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...